Platelets for advanced drug delivery in cancer.

Abstract

INTRODUCTION:

Cancer-related drug expenses are rising with the increasing cancer incidence and cost may represent a severe challenge for drug access for patients with cancer. Consequently, strategies for increasing therapeutic efficacy of already available drugs may be essential for the future health-care system.

AREAS COVERED:

In this review, we have investigated the potential for the use of platelets as drug-delivery systems. We searched PubMed and Google Scholar to identify relevant papers written in English and published up to January 2023. Papers were included at the authors' discretion to reflect an overview of state of the art.

EXPERT OPINION:

It is known that cancer cells interact with platelets to gain functional advantages including immune evasion and metastasis development. This platelet-cancer interaction has been the inspiration for numerous platelet-based drug delivery systems using either drug-loaded or drug-bound platelets, or platelet membrane-containing hybrid vesicles combining platelet membranes with synthetic nanocarriers. Compared to treatment with free drug or synthetic drug vectors, these strategies may improve pharmacokinetics and selective cancer cell targeting. There are multiple studies showing improved therapeutic efficacy using animal models, however, no platelet-based drug delivery systems have been tested in humans, meaning the clinical relevance of this technology remains uncertain.

• Authors: Daniel Cacic, Tor Hervig, Håkon Reikvam
• Journal: Expert opinion on drug delivery (Expert Opin Drug Deliv) Vol. 20 Issue 5 Pg. 673-688 (05 2023) ISSN: 1744-7593 [Electronic] England
• PMID: 37212640 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents

Topics

• Animals
• Humans
• Blood Platelets
• Neoplasms (drug therapy)
• Drug Delivery Systems
• Antineoplastic Agents (therapeutic use)
• Models, Animal